Atara Biotherapeutics, Inc.·4

Nov 17, 4:15 PM ET

Newell Joe 4

4 · Atara Biotherapeutics, Inc. · Filed Nov 17, 2021

Insider Transaction Report

Form 4
Period: 2021-11-15
Newell Joe
Chief Tech. Operations Officer
Transactions
  • Sale

    Common Stock

    2021-11-15$17.71/sh7,000$124,004116,429 total
  • Exercise/Conversion

    Common Stock

    2021-11-15$12.15/sh+3,500$42,525123,429 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-11-152,79232,083 total
    Exercise: $12.15Exp: 2030-02-28Common Stock (2,792 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-11-157089,917 total
    Exercise: $12.15Exp: 2030-02-28Common Stock (708 underlying)
Footnotes (3)
  • [F1]Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020.
  • [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.62 to $17.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4